The stages in standardizing erythropoietin preparations

Preparations of recombinant human erythropoietin (rhEPO) are included in the list of vital and essential drugs for medical use. When evaluating the quality of EPO preparations during the manufacturing process, under the state marketing authorization and certification procedures, in order to confirm their quality in terms of assay (specific activity), identification, dimer and high-molecular related substances content, sialic acids, it is required to use erythropoietin reference standard. The present article describes various stages of the development of erythropoietin reference standards. It provides the comparative description of the existing methods for evaluating the quality of erythropoietin preparations using reference standards. The necessity of the development and validation of national erythropoietin reference standard is justified.

препараты эритропоэтина, показатели качества, биологическая активность, метод оценки, точность определения, разработка и аттестация стандартного образца, erythropoietin preparations, quality indicators, biological activity, methods of evaluation, accuracy of determination, development and certification of a reference standard

1. Распоряжение Правительства Российской Федерации от 30 декабря 2014 г. № 2782-р.

2. Brines M., Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005; 6 (6): 484-94.

3. Ahmad R., Hand M. Recombinant erythropoietin for the anemia of chronic renal failure. N Engl J Med. 1987; 317(3): 169-70.

4. Zehnder C., Blumberg A. Treatment of renal anemia using human erythropoietin. Dtsch Med Wochenschr. 1987; 112(23): 938-9.

5. Ostrvica E., Mesic E., Ostrvica D., Delic J., Delic-Custendil S., Hukic F. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta. Med Arh. 2010; 64(1): 4-6.

6. Меркулов В.А., Солдатов А.А., Авдеева Ж.И., Алпатова Н.А., Гайдерова Л.А., Яковлев А.К., Медуницын Н.В. Препараты рекомбинантных эритропоэтинов и их характеристика. Биопрепараты 2013; (3): 4-11.

7. Бабичева Л.Г., Поддубная И.В. Лечение анемии в онкологии: роль нового стимулятора эритропоэза Аранесп (дарбэпоэтин альфа). Современная онкология 2007; 9(3): 69-74.

8. Милованов Ю.С., Козловская Л.В., Николаев А.Ю., Милованова Л.Ю. Анемия у больных с хронической почечной недостаточностью: принципы терапии. Лечащий врач 2005; (10): 18-24.

9. Henry D.H., Dahl N.V., Auerbach M.A. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol. 2012; 87(3): 308-10.

10. Casati S., Passerini P., Campise M.R., Graziani G., Cesana B., Perisic M., Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J. 1987; 295(6605): 1017-20.

11. European Parmacopoeia 7.0 «Erythropoietin Concentrated Solution». 2008; 1946-1950.

12. Об обращении лекарственных средств. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 13.07.2015).

13. Cotes P.M., Bangham D.R. The international reference preparation of erythropoietin. Bull World Health Organ. 1966; 35: 751-60.

14. Bruick R.K. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev. 2003; 17:2614-23.

15. Annable L., Cotes P.M., Mussett M.V. The second international reference preparation of erythropoietin., human., urinary., for bioassay. Bull World Health Organ. 1972; 47: 99-112.

16. Storring P.L., Gaines Das R.E. The International standard for recombinant DNA-derived erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol. 1992; 134: 459-84.

17. Storring P.L., Tiplady R.J., Gaines Das R.E., Rafferty B., Mistry Y.G. Lectin-binding assays for the isoforms of human erythropoietin: comparison of urinary and four recombinant erythropoietins. J Endocrinol. 1996; 150(3): 401-12.

18. Storring P.L., Tiplady R.J., Gaines Das R.E., Stenning B.E., Lamikanra A., Rafferty B., Lee J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998; 100(1): 79-89.

19. Bristow A.F. Collaborative study for the establishment of a biological reference preparation for erythropoietin. Pharmeuropa Bio. 1996; 97(2): 31-48.

20. Annual report 2014 European Directorate for the Quality of Medicines & HealthCare (EDQM).

21. Государственный реестр лекарственных средств. Available from: http://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=%D0%A D%D0%BF%D0%BE%D1%8D%D1%82%D0%B8%D0%BD&lf=&Tra deNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1&order=RegDate&orderType=desc&RegType=&pageNum=4.